Harmony Biosciences HRMY
$32.59 −$0.39 (-1.18%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $32.59 0.00%
Open$32.68
Prev close$32.98
Day range$32.51 – $33.43
Volume582.6K
Market cap$1.91B
P/E (TTM)10.8
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$268.92M+12.3% YoY
Operating profit$54.20M-17.2% YoY
Net profit$48.20M-5.2% YoY
Diluted EPS$0.81-6.9% YoY
Free cash flow$76.69M-29.4% YoY
Operating cash flow$76.69M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin74.0%
Operating margin22.2%
Net margin18.1%
Return on equity18.7%
Return on assets13.3%
Return on invested capital15.1%
Current ratio3.44
Liabilities / assets27.5%
Cash & investments$771.14M
Total debt$149.10M
Net cash (debt)$622.03M
Free cash flow / sales32.6%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $268.92M | $261.28M | $215.39M | $868.45M | $243.78M |
| Total Operating Revenue | $268.92M | $261.28M | $215.39M | $868.45M | $243.78M |
| Cost of Revenue | $80.69M | $63.20M | $44.51M | $198.34M | $68.55M |
| Gross Profit | $188.23M | $198.08M | $170.88M | $670.11M | $175.23M |
| Operating Expense | $134.03M | $108.77M | $133.58M | $461.64M | $136.67M |
| Selling and Admin Expenses | $62.37M | $62.17M | $64.20M | $272.05M | $86.74M |
| -Selling & Marketing Expense | $34.72M | $34.12M | $31.69M | $119.51M | $29.18M |
| -General & Admin Expense | $27.65M | $28.05M | $32.51M | $152.54M | $57.56M |
| Research & Development | $71.66M | $46.60M | $69.38M | $189.59M | $49.93M |
| Operating Profit | $54.20M | $89.32M | $37.29M | $208.47M | $38.56M |
| Net Non-Operating Interest Income (Expense) | $5.37M | $4.00M | $2.52M | $7.28M | $2.31M |
| Non-Operating Interest Income | $8.43M | $7.07M | $5.76M | $21.92M | $5.85M |
| Non-Operating Interest Expense | $3.06M | $3.07M | $3.23M | $14.65M | $3.55M |
| Other Income (Expense) | -$316,000.00 | -$53,000.00 | -$127,000.00 | -$680,000.00 | -$105,000.00 |
| Other Non-Operating Income (Expenses) | -$316,000.00 | -$53,000.00 | -$127,000.00 | -$680,000.00 | -$105,000.00 |
| Pretax Profit | $59.25M | $93.27M | $39.69M | $215.06M | $40.76M |
| Tax | $11.05M | $17.83M | $7.20M | $56.38M | $18.27M |
| Net Profit | $48.20M | $75.43M | $32.49M | $158.69M | $22.49M |
| Profit from Continuing Operations | $48.20M | $75.43M | $32.49M | $158.69M | $22.49M |
| Net Income to Parent Company | $48.20M | $75.43M | $32.49M | $158.69M | $22.49M |
| Net Income to Common Stockholders | $48.20M | $75.43M | $32.49M | $158.69M | $22.49M |
| Basic EPS | $0.83 | $1.30 | $0.56 | $2.76 | $0.39 |
| Diluted EPS | $0.81 | $1.28 | $0.55 | $2.71 | $0.38 |
| Special Income (Charges) | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.48B | $1.37B | $1.27B | $1.27B | $1.27B |
| Total Current Assets | $934.83M | $814.33M | $778.82M | $907.01M | $907.01M |
| Cash and Cash Equivalents & Short-Term Investments | $771.14M | $667.79M | $640.92M | $775.34M | $775.34M |
| -Cash and Cash Equivalents | $647.10M | $549.77M | $589.40M | $752.50M | $752.50M |
| -Short Term Investments | $124.04M | $118.02M | $51.52M | $22.84M | $22.84M |
| Receivables | $127.74M | $111.00M | $108.22M | $96.79M | $96.79M |
| -Accounts Receivable | $127.74M | $111.00M | $108.22M | $96.79M | $96.79M |
| Prepaid Assets | $18.10M | $19.31M | $16.80M | $16.01M | $16.01M |
| Inventory | $5.87M | $6.36M | $5.28M | $5.36M | $5.36M |
| Other Current Assets | $11.98M | $9.88M | $7.60M | $13.52M | $13.52M |
| Total Non-Current Assets | $543.42M | $558.75M | $493.01M | $364.62M | $364.62M |
| Investments and Advances | $280.47M | $294.67M | $229.56M | $107.13M | $107.13M |
| -Available for Sale Securities | $280.47M | $294.67M | $229.56M | $107.13M | $107.13M |
| Goodwill and Other Intangible Assets | $71.54M | $77.50M | $83.46M | $89.42M | $89.42M |
| Non-Current Deferred Assets | $161.37M | $156.77M | $153.56M | $149.70M | $149.70M |
| Other Non-Current Assets | $30.05M | $29.82M | $26.43M | $18.37M | $18.37M |
| Total Liabilities | $406.01M | $373.84M | $361.48M | $401.41M | $401.41M |
| Total Current Liabilities | $271.54M | $234.07M | $217.34M | $252.13M | $252.13M |
| Payables | $26.92M | $21.68M | $28.60M | $17.69M | $17.69M |
| -Accounts Payable | $26.92M | $21.68M | $28.60M | $17.69M | $17.69M |
| Current Accrued Expenses | $208.06M | $169.13M | $150.11M | $191.04M | $191.04M |
| Short-Term Debt and Capital Lease Obligation | $20.00M | $20.00M | $20.00M | $20.00M | $20.00M |
| -Current Debt | $20.00M | $20.00M | $20.00M | $20.00M | $20.00M |
| Other Current Liabilities | $1.68M | $11.17M | $11.91M | $4.96M | $4.96M |
| Total Non-Current Liabilities | $134.47M | $139.77M | $144.14M | $149.28M | $149.28M |
| Long Term Debt and Capital Lease Obligation | $129.10M | $133.96M | $138.81M | $143.66M | $143.66M |
| -Long Term Debt | $129.10M | $133.96M | $138.81M | $143.66M | $143.66M |
| Other Non-Current Liabilities | $5.37M | $5.81M | $5.32M | $5.62M | $5.62M |
| Total Equity | $1.07B | $999.24M | $910.35M | $870.22M | $870.22M |
| Stockholders' Equity | $1.07B | $999.24M | $910.35M | $870.22M | $870.22M |
| Capital Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Common Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| Additional Paid-In Capital | $757.15M | $731.15M | $717.37M | $708.97M | $708.97M |
| Retained Earnings | $317.02M | $268.82M | $193.39M | $160.90M | $160.90M |
| Gains/Losses Not Affecting Retained Earnings | -$1.94M | -$727,000.00 | -$413,000.00 | $346,000.00 | $346,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $76.69M | $92.43M | $27.76M | $348.20M | $126.15M |
| Net cash flow from continuing operations | $76.69M | $92.43M | $27.76M | $348.20M | $126.15M |
| Net Income from Continuing Operations | $48.20M | $75.43M | $32.49M | $158.69M | $22.49M |
| Depreciation & Depletion & Amortization | $5.97M | $5.97M | $5.97M | $25.34M | $7.43M |
| Deferred Tax | -$4.60M | -$3.20M | -$3.86M | -$7.30M | $7.38M |
| Other Non-Cash Items | $25.76M | $1.07M | $32.40M | $36.29M | $5.13M |
| Change in Working Capital | -$5.96M | $4.25M | -$49.63M | $91.82M | $74.04M |
| -Change in Receivables | -$16.74M | -$2.77M | -$11.44M | -$13.75M | $3.86M |
| -Change in Inventory | $489,000.00 | -$1.08M | $76,000.00 | $1.84M | $1.53M |
| -Change in Prepaid Assets | -$1.54M | -$7.85M | -$3.00M | $31.79M | $24.85M |
| -Change in Payables and Accrued Expense | $5.24M | -$6.92M | $10.91M | $3.95M | -$8.65M |
| -Change in Other Current Liabilities | $6.60M | $22.87M | -$46.18M | $67.99M | $52.45M |
| Net cash flow from investing | $7.68M | -$131.50M | -$183.65M | -$39.65M | -$17.63M |
| Net Cash Flow from Continuing Investing Activities | $7.68M | -$131.50M | -$183.65M | -$39.65M | -$17.63M |
| Net PPE Purchase and Sale | $0.00 | $0.00 | $0.00 | -$310,000.00 | -$107,000.00 |
| Net Investment Purchase and Sale | $7.68M | -$131.50M | -$151.65M | -$5.09M | $1.72M |
| Net Other Investing Changes | $0.00 | $0.00 | -$32.00M | -$15.00M | $0.00 |
| Financing Cash Flow | $12.96M | -$558,000.00 | -$7.22M | -$9.05M | -$3.02M |
| Net Cash Flow from Continuing Financing Activities | $12.96M | -$558,000.00 | -$7.22M | -$9.05M | -$3.02M |
| Net Issuance Payments Of Debt | -$5.00M | -$5.00M | -$5.00M | -$16.25M | -$5.00M |
| Proceeds from Stock Option Exercised | $17.96M | $5.52M | $347,000.00 | $10.21M | $2.65M |
| Net Other Financing Charges | $0.00 | -$1.08M | -$2.57M | -$3.00M | -$663,000.00 |
| Ending Cash Balance | $647.37M | $550.04M | $589.67M | $752.77M | $752.77M |
| Net Change in Cash | $97.33M | -$39.63M | -$163.10M | $299.50M | $105.50M |
| Beginning Cash Balance | $550.04M | $589.67M | $752.77M | $453.27M | $647.27M |
| Free Cash Flow | $76.69M | $92.43M | $27.76M | $347.89M | $126.04M |
| Net Business Purchase and Sale | – | – | – | -$19.25M | -$19.25M |
| Net Common Stock Issuance | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on HRMY.
Sign in to join the discussion.